XML 66 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Schedule of Concentrations of Credit Risk and Significant Customers The following customers accounted for over 10% of total gross product revenue during three and nine months ended September 30, 2024. As Rezdiffra was made commercially available in April 2024, there were no sales and no corresponding customer concentrations in 2023.
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Customer A
38 %— %38 %— %
Customer B
21 %— %21 %— %
Customer C
16 %— %16 %— %
Customer D
11 %— %12 %— %
Schedule of the Outstanding Securities not Included in the Computation of Diluted Net Loss Per Common Share as their Inclusion would be Anti-dilutive The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
Outstanding at September 30,
20242023
Common stock options1,701,6182,518,612
Restricted stock units502,867311,767
Performance-based restricted stock units235,520150,000
Preferred stock2,369,7972,369,797
Warrants3,625,24419,454